The latest price of erdafitinib in 2024

Erdafitinib is an oral, targeted inhibitor used to treat a specific type of advanced or metastatic urothelial carcinoma (urothelial carcinoma). This drug works by inhibiting the activity of the FGFR family of receptors. FGFR (fibroblast growth factor receptor) is a receptor involved in cell growth, proliferation and angiogenesis, and erdafitinib can prevent the growth and spread of tumor cells by targeting overactivated FGFR.

Erdafitinib is not currently on the market in China, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, which costs more than 20,000 yuan and needs to be purchased through Hong Kong pharmacies. Foreign generic drugs are relatively cheaper, mainly the Lao version and the Bangladesh Yaopin International version, with prices ranging from a few hundred yuan to more than 2,000 yuan, and the ingredients of the original drug and the generic drug are basically the same.

Advanced urothelial cancer is a common but difficult-to-treat type of cancer that often goes undetected in its early stages, so patients are often not diagnosed until the cancer has progressed to an advanced stage. In this case, treatment options are relatively limited, and conventional treatments such as chemotherapy and radiotherapy have limited effectiveness and come with many side effects.

Erdafitinib is unique in its specificity. It is primarily used in patients with advanced urothelial cancer who have FGFR gene abnormalities, including gene mutations or copy number increases. By targeting this specific molecular pathway, erdafitinib can more effectively inhibit tumor growth and have better efficacy and tolerability than traditional treatment options.

However, like all medications, erdafitinib may cause some side effects. Common side effects include fatigue, nausea, diarrhea, rash, etc., as well as some potentially more serious adverse reactions, such as high blood pressure, visual impairment, etc. Therefore, before using erdafitinib, doctors usually conduct a detailed evaluation of the patient and carefully weigh the benefits and risks of treatment.